| Bioactivity | Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon[1][2]. |
| Invitro | Trabedersen (1-80 μM; 7 days) reduces TGF-β2 secretion in human pancreatic cancer cell line Hup-T3 with an IC50 in the low μM range, clearly inhibits cell proliferation, and completely blocks migration of pancreatic cancer cells[2]. Trabedersen reverses TGF-β2-mediated immunosuppression of pancreatic cancer cells[2]. Cell Proliferation Assay[2] Cell Line: |
| In Vivo | Trabedersen (initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week; i.p.) treatment significantly reduces tumor growth, lymph node metastasis and angiogenesis in an orthotopic mouse model of metastatic pancreatic cancer[2]. Animal Model: |
| Name | Trabedersen |
| CAS | 925681-61-4 |
| Sequence | DNA, d(P-thio)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A) |
| Molar Mass | 5770.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Luc Vallières. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. IDrugs. 2009 Jul;12(7):445-53. [2]. Karl-Hermann Schlingensiepen, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011 Jun;102(6):1193-200. |